These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 6222234)

  • 1. Irreversible interaction of beta-haloalkylamine derivatives with dopamine D1 and D2 receptors.
    Cross AJ; Waddington JL; Ross ST
    Life Sci; 1983 Jun; 32(24):2733-40. PubMed ID: 6222234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kainic acid lesions dissociate [3H] spiperone and [3H]cis-flupenthixol binding sites in rat striatum.
    Cross AJ; Waddington JL
    Eur J Pharmacol; 1981 May; 71(2-3):327-32. PubMed ID: 7250192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective and stereospecific interactions of R-SK & F 38393 with [3H]piflutixol but not [3H]spiperone binding to striatal D1 and D2 dopamine receptors: comparisons with SCH 23390.
    O'Boyle KM; Waddington JL
    Eur J Pharmacol; 1984 Mar; 98(3-4):433-6. PubMed ID: 6144559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preferential inhibition of ligand binding to calf striatal dopamine D1 receptors by SCH 23390.
    Cross AJ; Mashal RD; Johnson JA; Owen F
    Neuropharmacology; 1983 Nov; 22(11):1327-9. PubMed ID: 6141534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of 3H-cis-flupenthixol binding to calf brain membranes.
    Cross AJ; Owen F
    Eur J Pharmacol; 1980 Aug; 65(4):341-7. PubMed ID: 7408943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Demonstration of neuroleptic receptor sites in mouse brain by autoradiography.
    Höllt V; Schubert P
    Brain Res; 1978 Jul; 151(1):149-53. PubMed ID: 679000
    [No Abstract]   [Full Text] [Related]  

  • 7. Receptor pharmacology. Its use in neuroleptic research.
    Hyttel J
    Acta Psychiatr Belg; 1987; 87(5):535-51. PubMed ID: 2897759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irreversible blockade of striatal dopamine receptors in vivo by a derivative of alpha-flupenthixol.
    Schuster DI; Holden WL; Narula AP; Murphy RB
    Eur J Pharmacol; 1982 Feb; 77(4):313-6. PubMed ID: 7060641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of 3H-cis-flupenthixol binding in rat striatum.
    Murrin LC
    Life Sci; 1983 Nov; 33(22):2179-86. PubMed ID: 6645796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors.
    Fleminger S; Rupniak NM; Hall MD; Jenner P; Marsden CD
    Biochem Pharmacol; 1983 Oct; 32(19):2921-7. PubMed ID: 6138043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relation between brain D2-dopamine receptors and 3H-spiperone binding sites of intact lymphocytes].
    Noguchi-kuno SA; Nakata C; Nishitani H
    Rinsho Shinkeigaku; 1983 Sep; 23(9):814-8. PubMed ID: 6232031
    [No Abstract]   [Full Text] [Related]  

  • 12. Biochemical and pharmacological differentiation of neuroleptic effect on dopamine D-1 and D-2 receptors.
    Hyttel J; Christensen AV
    J Neural Transm Suppl; 1983; 18():157-64. PubMed ID: 6135740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guanine nucleotides reveal differential actions of ergot derivatives at D-2 receptors labelled by [3H]spiperone in striatal homogenates.
    Gundlach AL; Krstich M; Beart PM
    Brain Res; 1983 Nov; 278(1-2):155-63. PubMed ID: 6227373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
    Hancock AA; Marsh CL
    Mol Pharmacol; 1984 Nov; 26(3):439-51. PubMed ID: 6238230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent increase in striatal dopamine stimulated adenylate cyclase activity persists for more than 6 months but disappears after 1 year following withdrawal from 18 months cis-flupenthixol intake.
    Murugaiah K; Fleminger S; Theodorou A; Jenner P; Marsden CD
    Biochem Pharmacol; 1983 Sep; 32(17):2495-9. PubMed ID: 6684429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further evidence that 3H-cis(Z)flupenthixol binds to the adenylate cyclase-associated dopamine receptor (D-1) in rat corpus striatum.
    Hyttel J
    Psychopharmacology (Berl); 1980 Jan; 67(1):107-9. PubMed ID: 6768074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions of dopamine agonists with brain D1 receptors labeled by 3H-antagonists. Evidence for the presence of high and low affinity agonist-binding states.
    Leff SE; Hamblin MW; Creese I
    Mol Pharmacol; 1985 Feb; 27(2):171-83. PubMed ID: 3969066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparisons between the in vitro binding of two substituted benzamides and two butyrophenones to dopamine-D2 receptors in the rat striatum.
    Hall H; Wedel I
    Acta Pharmacol Toxicol (Copenh); 1986 May; 58(5):368-73. PubMed ID: 2943136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of dopamine "D3" and "D4" binding sites, labelled with [3H]2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene, as high agonist affinity states of the D1 and D2 dopamine receptors, respectively.
    Urwyler S; Markstein R
    J Neurochem; 1986 Apr; 46(4):1058-67. PubMed ID: 2936868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of the enantiomers of SK&F 83566 as specific and stereoselective antagonists at the striatal D-1 dopamine receptor: comparisons with the D-2 enantioselectivity of Ro 22-1319.
    O'Boyle KM; Waddington JL
    Eur J Pharmacol; 1984 Oct; 106(1):219-20. PubMed ID: 6241567
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.